FDA says Glaxo failed to report Avandia data
WASHINGTON (Reuters) - GlaxoSmithKline Plc failed to report some post-marketing data on its diabetes drug Avandia, the U.S. Food and Drug Administration said in a warning to the company released on Tuesday.
<p><img src="http://feeds.reuters.com/~a/reuters/businessNews?i=VxG4s9" border="0"></img> (http://feeds.reuters.com/~a/reuters/businessNews?a=VxG4s9)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/businessNews?i=Vo79jTG" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=Vo79jTG) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=9UywVeg" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=9UywVeg) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=xE7rCtg" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=xE7rCtg)
</div><img src="http://feeds.reuters.com/~r/reuters/businessNews/~4/266381950" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/266381950/idUSWBT00871320080408